ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Systemic Inflammatory"

  • Abstract Number: 122 • 2020 Pediatric Rheumatology Symposium

    Systemic Inflammation and Cognitive Dysfunction in jSLE Patients

    Sara Ganhão 1, Mariana Rodrigues2, Beatriz Silva 1, Francisca Aguiar 1, Margarida Figueiredo-Braga 1 and Iva Brito 1, 1Centro Hospitalar de São João, Oporto, Portugal, 2Porto, Portugal

    Background/Purpose: Neurocognitive dysfunction (NCD) is one of the most commonly reported neuropsychiatric symptoms in patients with juvenile systemic lupus erythematosus (SLE), even without overt CNS…
  • Abstract Number: 992 • 2018 ACR/ARHP Annual Meeting

    Epigallocatechin-3-Gallate (EGCG) Suppresses Systemic Inflammation By Inhibiting IL-6-Induced STAT3 Activation in Cultured Hepatocytes and in Liver Tissue of Adjuvant-Induced Arthritis (AIA) Rats

    Anil K. Singh1, Sabrina Fechtner2, Dorothy Wang2, Mukesh Chourasia3 and Salahuddin Ahmed2,4, 1Washington State University, College of Pharmacy, Spokane, WA, 2Department of Pharmaceutical Sciences, Washington State University, College of Pharmacy, Spokane, WA, 3Department of Pharmacoinformatics,, National lnstitute of Pharmaceutical Education and Research, Hajipur,, India, 4Division of Rheumatology, University of Washington, Division of Rheumatology, School of Medicine, Seattle, WA

    Background/Purpose: In rheumatoid arthritis (RA), the pro-inflammatory cytokine interleukin-6 (IL-6) induces systemic inflammation by activating hepatocytes through IL-6 receptor (IL-6R)- mediated JAK/STAT3 signaling pathway. The…
  • Abstract Number: 84 • 2017 ACR/ARHP Annual Meeting

    Physiological Autoantibodies Against the Endthelin Receptor Type-a Are Critically Involved in the Homeostasis of Immune Cells

    Otávio Cabral-Marques1, Harald Heidecke2, Frank Petersen3, Xinhua Yu4 and Gabriela Riemekasten5, 1Department of Rheumatology, Vasculitis Center UKSH, University of Lübeck, Luebeck, Germany, 2CellTrend GmbH Luckenwalde, Luckenwalde, Germany, 3Research Centre Borstel, Borstel, Germany, 4Lung Centre Borstel, a Leibniz institute, Borstel, Germany, 5Department of Rheumatology, Universitatsklinikum Schleswig-Holstein, Lubeck, Germany

    Background/Purpose: G protein-coupled receptors (GPCRs) are a family of integral membrane proteins mediating cell trafficking and cellular homeostasis. In the last decades, several functional autoantibodies…
  • Abstract Number: 2197 • 2017 ACR/ARHP Annual Meeting

    Systemic Inflammation and Physical Function in Knee Osteoarthritis

    Devyani Misra1, Carrie Brown2, Roger A. Fielding3, Tuhina Neogi4, Michael C. Nevitt5, Cora E. Lewis6, James Torner7 and David T. Felson4, 1Medicine, Section of, Boston University School of Medicine, Boston, MA, 2Boston University School of Public Health, Boston, MA, 3Nutrition, Exercise Physiology and Sarcopenia Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging, Tufts University, Boston, MA, 4Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA, 5Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, 6University of Alabama Birmingham, Birmingham, AL, 7University of Iowa, Iowa City, IA

    Background/Purpose: Knee osteoarthritis (OA) is a leading cause of functional limitation and disability in older adults. But why some knee OA patients develop functional limitation…
  • Abstract Number: 2230 • 2017 ACR/ARHP Annual Meeting

    Use of Prescription Opioids Among Patients with Systemic Inflammatory Diseases (SID) Versus Patients with Hypertension but No Sid

    Sarah Chen1, Candace H. Feldman2, Gregory Brill3, Yvonne C. Lee4, Rishi J. Desai5 and Seoyoung C. Kim6, 1Brigham and Women's Hospital, Boston, MA, 2Rheumatology, Brigham & Women's Hospital, Boston, MA, 3Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital/Harvard Medical School, Boston, MA, 4Rheumatology Immunology & Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 5Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital, Boston, MA, 6Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA

    Background/Purpose: Opioid prescribing in the U.S. has increased at an alarming rate amid uncertainty over effectiveness and rising concerns over safety of this practice. Patients…
  • Abstract Number: 172 • 2016 ACR/ARHP Annual Meeting

    S100A8/A9 Produced during Experimental Osteoarthritis Induces a Systemic Decrease in BM Monocytes and Increases Ly6C High Monocytes Locally in the Joint

    Niels Cremers, Edwin Geven, Arjen Blom, Annet Sloetjes, Irene Di Ceglie, Stephanie van Dalen, Giuliana Ascone, Martijn van den Bosch and Peter van Lent, Experimental Rheumatology, Radboud university medical center, Nijmegen, Netherlands

    Background/Purpose: In response to pro-inflammatory cytokines released locally during osteoarthritis (OA), such as the alarmins S100A8/A9, monocytes can be recruited from the bone marrow (BM)…
  • Abstract Number: 1492 • 2016 ACR/ARHP Annual Meeting

    Biomarker-Related Risk for Myocardial Infarction and Serious Infections in Patients with Rheumatoid Arthritis: A Population-Based Study

    Jeffrey Curtis1, Fenglong Xie2, Lang Chen2 and Huifeng Yun3, 1Division Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 2Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 3Epidemiology, University of Alabama at Birmingham School of Public Health, Birmingham, AL

    Background/Purpose: Serious infection events (SIE) and myocardial infarction (MI) are among the most concerning adverse events that occur in rheumatoid arthritis (RA) patients. The role…
  • Abstract Number: 2843 • 2016 ACR/ARHP Annual Meeting

    Prevalence of Anti-DFS70 Antibodies in Patients with and without Systemic Autoimmune Rheumatic Diseases

    Ora Shovman1, Boris Gilburd2, Chen Chayat3, Howard Amital1,4, Abdulla Watad5, Adi Guy5, Chelsea Bentow6, Michael Mahler6 and Yehuda Shoenfeld1,4, 1Zabludowitz Center for Autoimmune Diseases Sheba Medical Center, Zabludowitz Center for Autoimmune Diseases Sheba Medical Center, 52621, Tel Hashomer, Israel, Ramat Gan, Israel, 2Zabludowitz Center for Autoimmune Diseases Sheba Medical Center, Zabludowitz Center for Autoimmune Diseases Sheba Medical Center, 52621, Tel Hashomer, Israel, Ramat-Gan, Israel, 3Zabludowitz Center for Autoimmune Diseases Sheba Medical Center, 52621, Tel Hashomer, Israel, Ramat Gan, Israel, 4Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel, Tel-Aviv, Israel, 5Internal Medicine B, Internal Medicine B, Sheba Medical Center, 52621, Tel Hashomer, Israel, Ramat Gan, Israel, 6Research and Development, Inova Diagnostics, San Diego, CA

    Background/Purpose: Autoantibodies to the dense fine speckled 70 (DFS70) antigen are common among ANA (dense fine speckled pattern) positive healthy individuals and consequently reduce the…
  • Abstract Number: 3082 • 2016 ACR/ARHP Annual Meeting

    Macrophage Activation Syndrome Is Identified By Coagulopathy, Hyperferritinemia, Fever, and Cytopenia in Hospitalized Patients, Resulting in Poor Outcome

    Bita Shakoory1, Negin Mohtasham2, Matthew Mullen3, Richard Amdur4 and W. Winn Chatham5, 1None, MCLEAN, VA, 2Rheumatology Research Center, Tehran University of Medical Sciences, Tehran, Iran (Islamic Republic of), 3Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 4Surgery, George Washington University, Washington, DC, 5Medicine/Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: Macrophage activation syndrome (MAS) constitutes over 5% of multi-organ dysfunction syndrome in adults, leading to 60-70% mortality without early treatment. H-Score, the only validated…
  • Abstract Number: 622 • 2015 ACR/ARHP Annual Meeting

    Sjögren’s Syndrome Foundation Clinical Practice Guidelines for Management of Dry Eyes

    Frederick B Vivino1, Gary Foulks2, S. Lance Forstot3, Peter Donshik4, Joseph Forstot5, Michael Goldstein6, Michael Lemp7, J. Daniel Nelson8,9, Kelly K. Nichols10,11, Stephen C. Pflugfelder12, Jason Tanzer13, Penny Asbell14, Deborah S. Jacobs15,16, Katherine M Hammitt17 and Sjogren's Syndrome Foundation Clinical Practice Guidelines Committee, 1University of Pennsylvania, Philadelphia, PA, 2Department of Ophthalmology and Visual Sciences, University of Louisville, Louisville, KY, 3Corneal Consultants of Colorado, Littleton, CO, 4Department of Ophthalmology, University of Connecticut Health Center, Farmington, CT, 5Rheumatology Associates of South Florida, Boca Raton, FL, 6New England Eye Center, Tufts Medical Center, Boston, MA, 7Department of Ophthalmology, Georgetown University, Washington, DC, 8Ophthalmology, HealthPartners Specialty Center, St. Paul, MN, 9Dept. of Ophthalmology, University of Minnesota, St. Paul, MN, 10School of Optometry, The University of Alabama at Birmingham, Birmingham, AL, 11College of Optometry, (formerly) University of Houston, Houston, TX, 12Ocular Surface Center, Baylor College of Medicine, Cullen Eye Institute, Houston, TX, 13Department of Oral Health and Diagnostic Sciences, University of Connecticut School of Dental Medicine, Farmington, CT, 14Dept of Ophthalmology, Icahn School of Medicine at Mount Sinai, New York, NY, 15Boston Foundation for Sight, Needham, MA, 16Cornea and External Diseases, Massachusetts Eye and Ear, Boston, MA, 17Vice President of Medical and Scientific Affairs, Sjögren's Syndrome Foundation, Bethesda, MD

    Background/Purpose: Dry eyes can compromise quality of life in Sjogren’s Syndrome (SS) and is often one of the most troublesome symptoms.  Clinical practice guidelines were…
  • Abstract Number: 625 • 2015 ACR/ARHP Annual Meeting

    Sjögren’s Syndrome Foundation Clinical Practice Guidelines for Management of Systemic Disease

    Frederick B Vivino1, Steven E. Carsons2, Ann Parke3, Nancy Carteron4, Vidya Sankar5, Richard Brasington6, Robert Fox7, William Ehlers3, Michael Brennan8, Robert Hal Scofield9, Katherine M Hammitt10 and Sjogren's Syndrome Foundation Clinical Practice Guidelines Committee, 1Rheumatology, University of Pennsylvania, Philadelphia, PA, 2Rheumatology, Allergy and Immunology, Winthrop University Hospital, Mineola, NY, 3University of Connecticut, Farmington, CT, 4University of California, San Francisco, CA, 5Univeristy of Texas, San Antonio, TX, 6Washington University, St Louis, MO, 7Rheumatology Clinic, La Jolla, CA, 8Carolinas Medical Center, Charlotte, NC, 9Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation; Department of Medicine, University of Oklahoma Health Sciences Center; US Department of Veterans Affairs Medical Center, Oklahoma City, OK, 10Vice President of Medical and Scientific Affairs, Sjögren's Syndrome Foundation, Bethesda, MD

    Background/Purpose: There are currently no FDA approved immunomodulating agents available for treatment of the extraglandular manifestations of Sjogren’s (SS).  Clinical practice guidelines were developed for…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology